<DOC>
	<DOCNO>NCT01386957</DOCNO>
	<brief_summary>Idiopathic nephrotic syndrome ( INS ) frequent glomerular disease childhood . Currently , child INS treat onset steroid . The optimal duration dosage steroid therapy debate . For patient , challenge minimise potential side effect steroid , achieve good clinical response . The aim study assess benefit potential adverse effect prolong initial corticosteroid regimen , treatment initial episode . The result compare data obtain retrospectively . In addition genetic study undertake aim evaluate pharmacodynamics steroid treatment ultimate goal individualise treatment single patient . 1 . Study group : child age 6 month - 18 year , diagnose initial episode idiopathic nephrotic syndrome 2 . Control group : data child onset INS January 2007 December 2009 area study group treat short steroid regimen retrospectively analyse compare</brief_summary>
	<brief_title>Steroid Treatment Idiopathic Nephrotic Syndrome</brief_title>
	<detailed_description>Background Idiopathic nephrotic syndrome ( INS ) frequent glomerular disease childhood , incidence 2-4 case per 100,000 child . Currently , child INS treat onset steroid . Approximately 80 % case respond oral corticosteroid therapy , 75-80 % child experience relapse recur many year . The optimal duration dosage steroid therapy onset subsequent relapse debate . For patient , challenge minimise potential side effect steroid therapy ( hypertension , bone disease , Cushing syndrome , obesity , growth retardation , cataracts variety psychological , social behavioural disturbance ) achieve good clinical response . This particularly difficult begin illness , lack reliable indicator allow identification patient respond poorly experience frequent relapse . In 2006 Cochrane Collaboration publish first systematic review corticosteroid therapy childhood idiopathic nephrotic syndrome . They conclude child first episode steroid sensitive INS treat minimum three month , achieve reduction subsequent relapse rate . The fine border optimal dose steroid collateral effect overlook give result recent study ( relative patient chronic inflammatory bowel disease child acute lymphoblastic leukemia subject prolong cycle steroid therapy ) base pharmacogenetic evaluation diverse individual response steroid . Clinical data support concept collateral effect steroid exclusively dose relate , depend constitutional hypersensitivity resistance , time specific particular corticosteroid . This diverse individual response depend number factor . The activity corticosteroid mediate interaction DNA ( genomic mechanism ) direct interaction cellular membrane ( non-genomic mechanism ) . The genomic effect far important mediate interaction steroid specific cytoplasmic receptor ( GR ) . The binding steroid determines activation receptor translocation within nucleus induces ( transactivation ) inhibits ( transcriptional interference ) synthesis numerous regulatory protein . The mechanism transactivation likely responsible major part collateral effect ( suppression hypothalamic-hypophysial-adrenal axis , genesis glaucoma diabetes ) , anti-inflammatory effect part tie transcriptional inhibition ( reduced synthesis pro-inflammatory cytokine , cyclic oxygenase2 , inducible form nitrite synthesis finally reduction synthesis receptor Fc C3 ) . There individual diverse molecular anomaly gene glucocorticoid receptor ( hGR/NR3C1 ) bean uncover : example presence polymorphism gene hGR correlate receptor hyperactivity ( Bcl1 e N3635 ) relative resistance glucocorticoid receptor ( polymorphism ER22/23EK ) ; 15 mutation already identify associate corticosteroid resistance . These fact open interest possibility pharmacological research hypothesis able adjust steroid therapy response individual genetic make-up predict appearance side effect . AIM The aim study assess benefit potential adverse effect prolong initial corticosteroid regimen across four Italian region , treatment initial episode INS . The result compare data obtain retrospectively analysis control group INS , treat short steroid regimen previous 3 year area . In addition genetic study undertake aim evaluate pharmacogenetics pharmacodynamics steroid treatment ultimate goal individualise treatment single patient . Study population : 1 . Study group : child age 6 month - 18 year , diagnose initial episode idiopathic nephrotic syndrome ( proteinuria &gt; 40mg/m2/h urine protein/creatine ratio &gt; 2 mg/mg hypoalbuminemia &lt; 2.5g/dL ) . Subjects enrol first July 2011 30th June 2013 ; follow-up subject continue 24 month . 2 . Control group : data child onset INS January 2007 December 2009 area study group treat short steroid regimen retrospectively analyse compare . Data record anonymously online database . The epidemiological , clinical , therapeutic parameter collect intervention group , except pharmacogenetic pharmacodynamic test , behavioral questionnaire . All study group patient subject follow protocol : Induction therapy : prednisone 60mg/m2/day 2 divided dos . Patients achieve remission within 10 day , continue dosage 28th day , whereas patient achieve remission within 10 day , continue dosage 42nd day . Moreover , 3rd day remission prednisone give single morning dose . Maintenance therapy : Patients go remission induction therapy steroid taper 16 week period : - 40 mg/m2/alt day single morning dose 4 week , - 30 mg/m2/alt day single morning dose 2 week , - 22.5 mg/m2/alt day single morning dose 2 week , - 15 mg/m2/alt day single morning dose 2 week , - 7.5 mg/m2/alt day single morning dose 2 week , - 4.5 mg/m2/alt day single morning dose 4 week , - stop therapy . A subgroup patient ( estimate 100 ) undergo pharmacogenetic pharmacodynamic study . The pharmacogenetic study evaluate presence gene polymorphisms modifies number function receptor affinity steroid ( gene study show Tab 3 ) . The pharmacodynamic study evaluate vitro response steroid blood mononuclear cell : individual sensibility steroid detect steroid treatment compare clinical response , order tailor treatment future . Relapses . Relapses treat prolonged steroid regimen witch describe protocol per extenso . Patient monitoring : 1 . Clinical examination Height , weight , BMI , blood pressure Parent height record ( familial target ) ( onset , remission , 4th , 20th week , 6 , 12 , 18 , 24 month ) 2 . Biochemistry ( onset , 4th week , 24 month ) Blood CBC ; serum glycemia , urea , creatinine , uric acid , protein , albumin , cholesterol , HDL , LDL , triglyceride , a2globulins , gammaglobulins , PT , PTT , fibrinogen , Anti-Thrombin IIIÂ° , Na , K , Cl , Ca , P , blood sample pharmacogenetic pharmacodynamic study Urine Urine examination . Proteinuria creatininuria 24h sample 3 . Behavioral questionnaire ( onset , 4th , 6 , 12 , 24 month ) ASEBA CBCL Achenbach System Empirically Based Assessment Child Behavior Checklist . EQ-5D-PROXY EuroQol Group ( version parent ) PedsQL Pediatric Quality Life Inventory ( version parent child ) EQ-5D-Y EuroQol Group ( version child ) The following epidemiological therapeutical data collect Epidemiological data - Sex - Age onset - Season - Ethnicity - Days hospitalization . - Number blood test perform follow-up Therapeutic data - Time remission ( day ) , number relapse 6-12-24 month - Time total dose ( mg/m2 ) induction therapy - Time total dose ( mg/m2 ) maintenance therapy - Prednisone total dose end 2yrs follow-up - Albumin infusion ( g/kg/patient ) - Use albumin infusion diuretic - Number immunosuppressive drug associate prednisone ( total dose mg/kg )</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Nephrotic Syndrome</mesh_term>
	<mesh_term>Nephrosis</mesh_term>
	<mesh_term>Nephrosis , Lipoid</mesh_term>
	<criteria>1 . Age &gt; 6 month &lt; 18 year 2 . Idiopathic nephrotic syndrome 3 . Ethical committee approval 1 . Age &lt; 6 month &gt; 18 year 2 . Congenital nephrotic syndrome 3 . Secondary nephrotic syndrome ( postinfectious , SLE , SchonleinHenoch ) define clinical feature , low C3 C4 level , severe hypertension macrohematuria 4. nephrotic syndrome associate syndrome ( Dennys Drash , Frasier syndrome , et.cet ) Wilms'tumor .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Nephrotic Syndrome</keyword>
	<keyword>Steroid treatment</keyword>
	<keyword>Proteinuria</keyword>
	<keyword>Child</keyword>
</DOC>